It's a health challenge our scientists are relentlessly working to solve—preventing or delaying the onset of type 1 diabetes.

With 5-10% of people with diabetes having type 1, it's critical now more than ever for the right innovations and expertise to converge to help find a solution.

At Novo Nordisk, we're investing significant resources into improving our understanding of type 1 diabetes. With a long-held company aspiration to drive change to defeat diabetes – our research ranges from finding a cure to identifying reversal therapies.

Our research team led by Dr. Johnna Wesley in Seattle, WA, is exploring ways we can delay or possibly prevent the onset of this disease.